Technology
ONM-501
ONM-501 is a dual-activating STING (STimulator of INterferon Genes) agonist delivered to the tumor microenvironment to produce dendritic cell maturation, prime cytotoxic T cells, and induce a strong adaptive immune response.
Preclinical Data
Preclinical data shows evidence that ONM-501 prolongs STING activation with a low potential for systemic side effects, including cytokine storms. In murine models, ONM-501 has demonstrated antitumor efficacy, and when combined with checkpoint inhibition, produces a synergistic tumor cell death.
ONM-501 Cancer Trial
ONM-501 is currently being evaluated in a phase 1, multicenter, open label, non-randomized dose escalation and dose expansion trial to examine the maximum tolerated dose, minimum effective dose and/or recommended dose for expansion of intratumoral ONM-501 as a monotherapy and in combination with a PD-1 checkpoint inhibitor, cemiplimab, in patients with advanced solid tumors and lymphomas.